Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06000358
Other study ID # LUCACRIMUNO-001
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date April 1, 2023
Est. completion date March 31, 2026

Study information

Verified date August 2023
Source Lithuanian University of Health Sciences
Contact Marius Zemaitis, PhD, professor
Phone +37061256473
Email marius.zemaitis@kaunoklinikos.lt
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Lung cancer remains one of the most commonly diagnosed oncological diseases worldwide and the first in terms of mortality. Although immune checkpoint inhibitors form the backbone of current metastatic non-small cell lung cancer treatments, there is still no ideal predictive marker for its efficacy and patients still achieve suboptimal results in overall response and survival. While immune checkpoint inhibitors are known to shift systemic anti-tumor immune response from suppression to stimulation in some patients, the investigators hypothesize that this effect can be further enhanced by cryotherapy, especially in "cold" tumors. If proven successful, cryotherapy in combination with immunotherapy, could potentiate a more powerful immune response compared to systemic therapy alone, improve overall response rate, patients' survival without disease progression, and overall survival. The investigators, therefore, aim to use combined local tumor cryotherapy, combined with immune checkpoint inhibitor therapy to induce and evaluate systemic anti-tumor T lymphocyte response and achieve improved non-small cell lung cancer patient outcomes than with immunotherapy alone.


Recruitment information / eligibility

Status Recruiting
Enrollment 120
Est. completion date March 31, 2026
Est. primary completion date March 31, 2026
Accepts healthy volunteers No
Gender All
Age group 18 Years to 99 Years
Eligibility Inclusion Criteria: - Patients with Eastern Cooperative Oncology Group (ECOG) performance score 0 - 1; - Patients with histologically confirmed metastatic non-small cell lung cancer and PD-L1 expression on tumor cells was evaluated; - CT examination shows measurable tumor formations according to the RECIST 1.1 criteria; - Primary lung tumor or metastasis accessible to flexible bronchoscopy; - Patients may have received surgery, adjuvant or neoadjuvant chemotherapy prior to the study if it was completed at least 12 months before relapse; - Patients informed about the purpose and course of the study and provided a written consent to participate. Exclusion Criteria: - Patients who refused to participate in the clinical trial and did not sign the informed consent form; - Men and women under the age of 18, pregnant women; - Patients belonging to a vulnerable social group; - High risk of general anesthesia, defined as American Society of Anesthesiologists (ASA) class 4 - 6; - Documented allergy to medications used during general and local anesthesia, systemic cancer treatment; - Patients previously treated with immune checkpoint inhibitors; - EGFR mutations or ALK translocations have been identified in patients; - Patients with previously diagnosed autoimmune diseases, active viral hepatitis, uncontrolled human immunodeficiency virus (HIV) infection or untreated tuberculosis; - Patients treated with immunosuppressive drugs, systemic corticosteroids, with equivalent doses of prednisolone exceeding 10 mg/day; - Patients with an increased risk of bleeding during an interventional procedure; - Acute untreated conditions that would make it impossible to perform an interventional lung procedure.

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Bronchoscopic cryotherapy
The cryotherapy procedure is performed before the start of systemic treatment, under visual (for endobronchial cryotherapy) or radial EBUS and fluoroscopy control (for transbronchial cryotherapy), ensuring the correct position of the cryoprobe in the tumor. After being placed in the correct position. After being placed in the correct position, the cryoprobe is cooled using CO2 and allowed to cool passively. The cooling-thawing stages are repeated for a total of 3 cycles.
Drug:
Pembrolizumab
As a standard of care, patients will receive pembrolizumab.
Platinum based chemotherapy
As a standard of care, patients will receive platinum-based chemotherapy in addition to pembrolizumab if PD-L1 expression is less than 50%.

Locations

Country Name City State
Lithuania Lithuanian University of Health Sciences Kaunas

Sponsors (2)

Lead Sponsor Collaborator
Lithuanian University of Health Sciences Research Council of Lithuania

Country where clinical trial is conducted

Lithuania, 

Outcome

Type Measure Description Time frame Safety issue
Primary Changes in T Lymphocyte Count and Function in Response to Cryotherapy and Immunotherapy Changes in T lymphocyte counts and function in peripheral venous blood assessed via flow cytometry 6 weeks
Secondary Necrotic cancer cell death A change in the concentration of High mobility group box 1 protein (HMGB-1) in venous blood 6 weeks
Secondary The influence of immune cell infiltration in tumor tissue on subsequent cryotherapy and immunotherapy treatment Number of tumor-infiltrating CD4 and CD8 lymphocytes in non-small cell lung cancer biopsy material by immunohistochemistry. 1 day
Secondary Objective response rate Assessed according to RECIST and iRECIST criteria 1 year
Secondary Progression-free survival The time from the first cycle of systemic treatment to radiologically confirmed disease progression 1 year
Secondary Overall survival The time from the first cycle of systemic treatment to death from any cause 1 year
Secondary Safety of bronchoscopic cryotherapy and immunotherapy Documentation and assessment of adverse treatment events according to Common Terminology Criteria for Adverse Events (CTCAE) version 5. 1 year
Secondary Changes in T Lymphocyte Function in Response to Cryotherapy and Immunotherapy Changes in T lymphocyte function in peripheral venous blood assessed via RNA expression 6 weeks
Secondary Changes in T Lymphocyte Effector Function in Response to Cryotherapy and Immunotherapy Changes in T lymphocyte effector function in peripheral venous blood evaluated via cytokine panels 6 weeks
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03668496 - A Study of SHR-1210 in Combination With Carboplatin + Paclitaxel in Subjects With Squamous NSCLC Phase 3
Active, not recruiting NCT03322072 - Calypso Guided High Precision Stereotactic Ablative Radiosurgery for Lung TUmours Using Real-Time Tumour Tracking & Respiratory Gating N/A
Recruiting NCT05497973 - Psychosocial eHealth in Advanced Lung Cancer N/A
Recruiting NCT06076005 - Lung Cancer ID (Identity) Study
Recruiting NCT05860296 - Testing Experimental Anti-cancer Drug SLC-391 With an Approved Immunotherapy Drug, Pembrolizumab, for Advanced Lung Cancers Phase 1/Phase 2
Recruiting NCT05311709 - Sotorasib in Advanced KRASG12C-mutated Non-small Cell Lung Cancer Patients With Comorbidities Phase 2
Completed NCT04825912 - Resilience Measurement in Older Adults With Late-Stage Lung Cancer N/A
Completed NCT03529851 - Feasibility of a Web-based Patient Reported Outcome Symptom Monitoring Application in Danish Lung Cancer Patients N/A
Completed NCT03558165 - Lung Cancer Next Generation Sequencing Using the Oncomine Comprehensive Assay
Completed NCT03076164 - A Phase 1/2 Trial of Trametinib and Erlotinib in Patients With EGFR-Mutant Lung Adenocarcinomas and Acquired Resistance to Erlotinib Phase 1/Phase 2
Not yet recruiting NCT03153358 - Icotinib Combined With SBRT for Patients With Metastatic Non-squamous NSCLC With EGFR Mutation Phase 2
Recruiting NCT04595734 - Liver Toxicity in Lung Cancer Patients Treated With Immune-checkpoint Inhibitors.
Recruiting NCT04519983 - Efficacy of SRT as Salvage Therapy in Patients With Brain Oligo-progression of EGFR-mutant Non-small Cell Lung Cancer After Failure of the Third-generation EGFR-TKIs Phase 2
Not yet recruiting NCT05701384 - Lazertinib 160mg in EGFR T790M NSCLC Phase 2
Withdrawn NCT03409341 - Personalizing Immune Checkpoint Inhibitor Therapy
Active, not recruiting NCT03728361 - Nivolumab and Temozolomide in Treating Patients With Recurrent or Refractory Small-Cell Lung Cancer or Advanced Neuroendocrine Cancer Phase 2
Not yet recruiting NCT06024941 - Re-induction of a Systemic Immune Response in Metastatic or Locally Recurrent Lung Cancer Phase 2
Recruiting NCT04669223 - Comparing Different Sizes of Small-bore Chest Drains in Malignant Pleural Effusion N/A
Recruiting NCT05996263 - Prognostic Value of Combined Approach Based on KEAP1/NFE2L2 Mutations and Pre-therapeutic FDG-PET/CT Radiomic Analysis in Advanced Non-small-cell Lung Cancer PDL1 ≥ 50% Treated With Pembrolizumab (PEMBROMIC)
Completed NCT04057196 - Self-System Therapy for Older Adults With Lung Cancer N/A